George Tidmarsh criticized Aurinia’s lupus drug in a later-retracted social media post. Elsewhere, the FDA approved a new ...

The funding lapse triggered by the U.S. government shutdown is the latest test for an agency that’s already dealt with ...

In a Phase 2 trial, a drug at the center of the $4.9 billion deal matched the type of weight loss trajectory seen in testing ...

A pact to offer “most favored nation” prices to state Medicaid programs and via direct-to-consumer channels doesn’t affect ...

Star hopes its drug, which is currently in late-stage testing, might prove a more convenient, longer-lasting alternative to ...

The biotech is starting up with partial rights to a drug that’s approved in multiple Asian countries and its executives see ...

The deal hands Genmab a drug that showed the potential in earlier testing to extend survival in head and neck cancer when ...

Decades of slow-moving research, along with broader failures of the healthcare system, have left millions of people in daily ...

The clearance of Inluriyo is another development among a group of oral medicines aiming to supplant a widely used, injectable ...

The trial failure removes from development a treatment Acadia acquired in a 2022 buyout and that was seen as a potential ...

A recent report from Back Bay Life Science Advisors shows a surge in testing of, and investment in, multifunctional ...

After reviewing existing published literature, the agency initiated the approval of Wellcovorin — which GSK stopped selling ...